The report “HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End-User (Laboratories, Hospitals, Physicians’ Offices & Clinics) — Global Forecast”, published by MarketsandMarkets™
Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.
The increasing number of cervical cancer cases and the growing aging population
Cervical cancer is considered to be the fourth most prevalent forms of cancer globally and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012. This figure is expected to reach to 609,270 new cases and 315,727 deaths by 2020. (Source: Globocan 2012). Approximately 26,000 new cancers attributable to HPV occur each year, 18,000 among females and 8,000 among males (Source: CDC). The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. This, in turn is expected to drive the HPV testing and Pap test market in the coming years.
HPV Testing and Pap Test Market Drivers:
Geographically, the HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.
Key players in the HPV testing and Pap test market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.). These players focus on inorganic and organic strategies such as product approvals & licenses, agreements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the HPV testing and Pap test market.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly